GILEAD SCIENCES DL-,001 | 54.930 / +0.22% |
Date/Time | 01/27 / 08:54 |
Chg. / Chg.(%) | 0.120 / +0.22% |
Bid | 54.530 / 600 |
Ask | 54.690 / 600 |
Open | 54.610 |
Previous Close | 54.810 |
High | 54.930 |
Low | 54.610 |
Volume [EUR] | 15,978.260 |
Volume [Units] | 291 |
Price fixings | 3 |
ISIN | US3755581036 |
Security | GIS |
Exchange | Stuttgart |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
TradeGate | 54.750 | ![]() |
1,176 |
Stuttgart | 54.930 | ![]() |
291 |
Frankfurt | 54.6500 | ![]() |
207 |
Hannover | 54.60 | ![]() |
100 |
gettex | 54.600 | ![]() |
100 |
Berlin | 54.58 | ![]() |
0 |
München | 54.89 | ![]() |
0 |
Düsseldorf | 54.59 | ![]() |
0 |
Hamburg | 54.60 | ![]() |
0 |
Lang & Schwa.. | 54.550 | ![]() |
|
NASDAQ | 66.7000 | ![]() |
7,125,214 |
Cboe US | 66.69 | ![]() |
561,682 |
IEX | 66.70 | ![]() |
352,106 |
Xetra | 55.21 | 16,730 | |
London Inter.. | 67.69 | 6,663 | |
Borsa Italia.. | 55.33 | 1,151 | |
Vienna Globa.. | 55.30 | 1,075 | |
Mexico | 1,333.00 | ![]() |
146 |
Borsa Italia.. | 54.71 | ![]() |
20 |
News
- NICE recommends Jyseleca® ▼(filgotinib) on NHS in landmark decision for rheumatoid arthritis
01/21/2021 / 08:08 - GlobeNewswire - Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and PD-1 Inhibitor Combination Therapy in Patients with Advanced Solid Tumors
01/13/2021 / 14:00 - GlobeNewswire - Gilead holds 25.54% of Galapagos shares
01/11/2021 / 22:01 - GlobeNewswire - Remdesivir could work against new COVID strains - Gilead
01/11/2021 / 15:21 - TeleTrader - Intercept Appoints Jared M. Freedberg as General Counsel and Secretary
01/11/2021 / 14:00 - GlobeNewswire